RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States
Jia, X., Zhao, Y., Carrico, J., Brodtkorb, T.-H., Mendelsohn, A., Lowry, S., Feldman, S., Armstrong, A., & Wu, JJ. (2018). Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States. Journal of managed care & specialty pharmacy, 24(10-a Suppl), S79. https://doi.org/10.18553/jmcp.2018.24.10-a.s1